{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T07:51:15Z","timestamp":1777103475486,"version":"3.51.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,17]]},"DOI":"10.7759\/cureus.64781","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T06:10:42Z","timestamp":1721283042000},"source":"Crossref","is-referenced-by-count":0,"title":["Use of Radiation Therapy for Ataxia-Telangiectasia Mutated (ATM)-Mutation Metastatic Renal Cell Carcinoma: A Case Report"],"prefix":"10.7759","author":[{"given":"Steven N","family":"Seyedin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garrett","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleen","family":"Garemanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Desiree","family":"Rafizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalia","family":"Kaakour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sami","family":"Dwabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Daneshvar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nataliya","family":"Mar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2018.10.002","article-title":"Trends in renal-cell carcinoma incidence and mortality in the United States in the last 2 decades: a SEER-based study","volume":"17","author":"Saad AM","year":"2019","unstructured":"Saad AM, Gad MM, Al-Husseini MJ, Ruhban IA, Sonbol MB, Ho TH. Trends in renal-cell carcinoma incidence and mortality in the United States in the last 2 decades: a SEER-based study. Clin Genitourin Cancer. 2019, 17:46-57.e5. 10.1016\/j.clgc.2018.10.002","journal-title":"Clin Genitourin Cancer"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel RL","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024, 74:12-49. 10.3322\/caac.21820","journal-title":"CA Cancer J Clin"},{"key":"ref3","unstructured":"Kidney cancer (Version 3.2024). NCCN. (2024). Accessed. May 8, 2024: https:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/kidney.pdf."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030565","article-title":"An update on the treatment of papillary renal cell carcinoma","volume":"15","author":"Chawla NS","year":"2023","unstructured":"Chawla NS, Sayegh N, Prajapati S, Chan E, Pal SK, Chehrazi-Raffle A. An update on the treatment of papillary renal cell carcinoma. Cancers (Basel). 2023, 15:565. 10.3390\/cancers15030565","journal-title":"Cancers (Basel)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_390038","article-title":"State of the art: multidisciplinary management of oligometastatic renal cell carcinoma","volume":"43","author":"Dason S","year":"2023","unstructured":"Dason S, Lacuna K, Hannan R, Singer EA, Runcie K. State of the art: multidisciplinary management of oligometastatic renal cell carcinoma. Am Soc Clin Oncol Educ Book. 2023, 43:e390038. 10.1200\/EDBK_390038","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref6","article-title":"Stereotactic body radiation therapy (SBRT) for metastatic renal cell carcinoma: a multi-institutional experience","volume":"7","author":"Singh R","year":"2020","unstructured":"Singh R, Ansinelli H, Sharma D, Jenkins J, Davis J, Sharma S, Vargo JA. Stereotactic body radiation therapy (SBRT) for metastatic renal cell carcinoma: a multi-institutional experience. J Radiosurg SBRT. 2020, 7:29-37.","journal-title":"J Radiosurg SBRT"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2019.05.007","article-title":"Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies","volume":"2","author":"Zaorsky NG","year":"2019","unstructured":"Zaorsky NG, Lehrer EJ, Kothari G, Louie AV, Siva S. Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies. Eur Urol Oncol. 2019, 2:515-23. 10.1016\/j.euo.2019.05.007","journal-title":"Eur Urol Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2021.100692","article-title":"Stereotactic ablative radiation therapy for oligoprogressive renal cell carcinoma","volume":"6","author":"Schoenhals JE","year":"2021","unstructured":"Schoenhals JE, Mohamad O, Christie A, et al.. Stereotactic ablative radiation therapy for oligoprogressive renal cell carcinoma. Adv Radiat Oncol. 2021, 6:100692. 10.1016\/j.adro.2021.100692","journal-title":"Adv Radiat Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00528-3","article-title":"Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial","volume":"22","author":"Tang C","year":"2021","unstructured":"Tang C, Msaouel P, Hara K, et al.. Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial. Lancet Oncol. 2021, 22:1732-9. 10.1016\/S1470-2045(21)00528-3","journal-title":"Lancet Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2021.12.001","article-title":"Phase II trial of stereotactic ablative radiation for oligoprogressive metastatic kidney cancer","volume":"5","author":"Hannan R","year":"2022","unstructured":"Hannan R, Christensen M, Hammers H, et al.. Phase II trial of stereotactic ablative radiation for oligoprogressive metastatic kidney cancer. Eur Urol Oncol. 2022, 5:216-24. 10.1016\/j.euo.2021.12.001","journal-title":"Eur Urol Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0792","article-title":"Genomic tumor correlates of clinical outcomes following organ-sparing chemoradiation therapy for bladder cancer","volume":"29","author":"Kamran SC","year":"2023","unstructured":"Kamran SC, Zhou Y, Otani K, et al.. Genomic tumor correlates of clinical outcomes following organ-sparing chemoradiation therapy for bladder cancer. Clin Cancer Res. 2023, 29:5116-27. 10.1158\/1078-0432.CCR-23-0792","journal-title":"Clin Cancer Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2020.1247","article-title":"Increased radiosensitivity of solid tumors harboring ATM and BRCA1\/2 mutations","volume":"54","author":"Kim KH","year":"2022","unstructured":"Kim KH, Kim HS, Kim SS, et al.. Increased radiosensitivity of solid tumors harboring ATM and BRCA1\/2 mutations. Cancer Res Treat. 2022, 54:54-64. 10.4143\/crt.2020.1247","journal-title":"Cancer Res Treat"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2020.06.002","article-title":"Safety and efficacy of nivolumab in patients with advanced clear cell renal cell carcinoma: results from the phase IIIB\/IV CheckMate 374 study","volume":"18","author":"McFarlane JJ","year":"2020","unstructured":"McFarlane JJ, Kochenderfer MD, Olsen MR, et al.. Safety and efficacy of nivolumab in patients with advanced clear cell renal cell carcinoma: results from the phase IIIB\/IV CheckMate 374 study. Clin Genitourin Cancer. 2020, 18:469-476.e4. 10.1016\/j.clgc.2020.06.002","journal-title":"Clin Genitourin Cancer"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02365","article-title":"Open-label, single-arm, Phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced non-clear cell renal cell carcinoma","volume":"39","author":"McDermott DF","year":"2021","unstructured":"McDermott DF, Lee JL, Ziobro M, et al.. Open-label, single-arm, Phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced non-clear cell renal cell carcinoma. J Clin Oncol. 2021, 39:1029-39. 10.1200\/JCO.20.02365","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00939","article-title":"Cabozantinib in combination with atezolizumab for advanced renal cell carcinoma: results from the COSMIC-021 study","volume":"39","author":"Pal SK","year":"2021","unstructured":"Pal SK, McGregor B, Su\u00e1rez C, et al.. Cabozantinib in combination with atezolizumab for advanced renal cell carcinoma: results from the COSMIC-021 study. J Clin Oncol. 2021, 39:3725-36. 10.1200\/JCO.21.00939","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00515-X","article-title":"Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial","volume":"17","author":"Armstrong AJ","year":"2016","unstructured":"Armstrong AJ, Halabi S, Eisen T, et al.. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol. 2016, 17:378-88. 10.1016\/S1470-2045(15)00515-X","journal-title":"Lancet Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.21869","article-title":"Evaluation of clear cell, papillary, and chromophobe renal cell carcinoma metastasis sites and association with survival","volume":"4","author":"Dudani S","year":"2021","unstructured":"Dudani S, de Velasco G, Wells JC, et al.. Evaluation of clear cell, papillary, and chromophobe renal cell carcinoma metastasis sites and association with survival. JAMA Netw Open. 2021, 4:e2021869. 10.1001\/jamanetworkopen.2020.21869","journal-title":"JAMA Netw Open"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.15586\/jkcvhl.v10i4.294","article-title":"Papillary renal cell carcinoma: demographics, survival analysis, racial disparities, and genomic landscape","volume":"10","author":"Ullah A","year":"2023","unstructured":"Ullah A, Yasinzai AQ, Daino N, et al.. Papillary renal cell carcinoma: demographics, survival analysis, racial disparities, and genomic landscape. J Kidney Cancer VHL. 2023, 10:33-42. 10.15586\/jkcvhl.v10i4.294","journal-title":"J Kidney Cancer VHL"},{"key":"ref19","article-title":"Radiobiology for the Radiologist","author":"Hall EJ","year":"2019","unstructured":"Hall EJ, Giaccia AJ. Radiobiology for the Radiologist. Wolters Kluwer, Philadelphia, Pennsylvania, US; 2019."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22189783","article-title":"Genetic aberrations of DNA repair pathways in prostate cancer: translation to the clinic","volume":"22","author":"Ghose A","year":"2021","unstructured":"Ghose A, Moschetta M, Pappas-Gogos G, Sheriff M, Boussios S. Genetic aberrations of DNA repair pathways in prostate cancer: translation to the clinic. Int J Mol Sci. 2021, 22:9783. 10.3390\/ijms22189783","journal-title":"Int J Mol Sci"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.5074","article-title":"Concurrent olaparib and radiotherapy in patients with triple-negative breast cancer: the phase 1 olaparib and radiation therapy for triple-negative breast cancer trial","volume":"8","author":"Loap P","year":"2022","unstructured":"Loap P, Loirat D, Berger F, et al.. Concurrent olaparib and radiotherapy in patients with triple-negative breast cancer: the phase 1 olaparib and radiation therapy for triple-negative breast cancer trial. JAMA Oncol. 2022, 8:1802-8. 10.1001\/jamaoncol.2022.5074","journal-title":"JAMA Oncol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2551","article-title":"Phase I and pharmacologic study of olaparib in combination with high-dose radiotherapy with and without concurrent cisplatin for non-small cell lung cancer","volume":"27","author":"de Haan R","year":"2021","unstructured":"de Haan R, van den Heuvel MM, van Diessen J, et al.. Phase I and pharmacologic study of olaparib in combination with high-dose radiotherapy with and without concurrent cisplatin for non-small cell lung cancer. Clin Cancer Res. 2021, 27:1256-66. 10.1158\/1078-0432.CCR-20-2551","journal-title":"Clin Cancer Res"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2946","article-title":"A pilot study of stereotactic body radiation therapy combined with cytoreductive nephrectomy for metastatic renal cell carcinoma","volume":"23","author":"Singh AK","year":"2017","unstructured":"Singh AK, Winslow TB, Kermany MH, et al.. A pilot study of stereotactic body radiation therapy combined with cytoreductive nephrectomy for metastatic renal cell carcinoma. Clin Cancer Res. 2017, 23:5055-65. 10.1158\/1078-0432.CCR-16-2946","journal-title":"Clin Cancer Res"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs629","article-title":"Combining radiotherapy and cancer immunotherapy: a paradigm shift","volume":"105","author":"Formenti SC","year":"2013","unstructured":"Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst. 2013, 105:256-65. 10.1093\/jnci\/djs629","journal-title":"J Natl Cancer Inst"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/264391-use-of-radiation-therapy-for-ataxia-telangiectasia-mutated-atm-mutation-metastatic-renal-cell-carcinoma-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T06:10:47Z","timestamp":1721283047000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/264391-use-of-radiation-therapy-for-ataxia-telangiectasia-mutated-atm-mutation-metastatic-renal-cell-carcinoma-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,17]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.64781","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,17]]}}}